A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.
Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.
At the MAD-ID and SIDP 2026 annual meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.
Emily Heil, PharmD, MS, FIDP, BCIDP, AAHIVP, discussed the growing prevalence of metallo-β-lactamase–producing organisms in the United States and highlighted emerging therapeutic strategies designed to overcome increasingly complex antimicrobial resistance mechanisms.
Preclinical in vitro and animal models remain essential for establishing antibiotic pharmacokinetic and pharmacodynamic targets, but experts say translating those findings into real-world patient care requires careful consideration of host factors, tissue penetration, and clinical context.
Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the Antimicrobials meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.
Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.
SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.
David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.
The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.
Quality improvement initiative at Henry Ford Health demonstrates streamlined workflow, rapid prior authorization, and low patient copayments; highlights opportunities for enhanced pharmacist involvement and education.
More than 80% of patients had drug-related problems, highlighting the need for inpatient antiretroviral stewardship.
Presented at MAD-ID 2025, Natt Patimavirujh, PharmD, supports fidaxomicin over vancomycin for high-risk groups, including transplant and chemotherapy patients.
Presented at MAD-ID by Mohammed Al Musawa, PharmD, BCIDP, the study found lower clinical success with imipenem-cilastatin-relebactam in obese patients, raising questions about dosing strategies.
At MAD-ID, Alyssa Cox, PharmD, showed fidaxomicin reduces 90-day recurrence by 68.3% versus vancomycin, with rates of 7.9% vs. 19% in 176 hospitalized patients.
At MAD-ID, Jose Alexander, MD, reports 98% susceptibility in ESBL E coli and 76% in K pneumoniae, underscoring the need for species-specific testing.
At MAD-ID 2025, Tiffany Lee, PharmD, presents multi-center findings showing no increase in AKI with higher initial dosing.
At MAD-ID 2025, William R Mikesell, PharmD, presented data showing 20% vs 16% treatment failure rates in doxycycline and minocycline groups.
Christina Lee, PharmD, and Julia Donahue, PharmD, analyzed 533 encounters revealing a 27.1% readmission rate in immunocompromised patients versus 14.1% in non-immunocompromised patients.
At MAD-ID, Dianne Nguyen, MD, shares Phase 3 data showing consistent tolerability of the microbiome therapy across high-risk patient populations
In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical success rate across a wide-range of infections and pathogens in an immunocompromised population.
At MAD-ID, Marc Scheetz, PharmD, discusses how PK/PD modeling and AUC-based strategies offer safer, more precise antibiotic therapy.
Logan Brock, PharmD, presents data at MAD-ID, showing limited diagnostic yield from routine fungal cultures and delayed results compared with standard methods.
At MAD-ID 2025, Kimberly Leuthner, PharmD, FIDSA, highlights the need for larger prospective studies amid limited current evidence.
At MAD-ID 2025, Jiye Park, PharmD, presents findings showing once-daily dosing is effective, with no added benefit from extended vancomycin use after antibiotics.
At MAD-ID 2025, Dakota Rorie, PharmD, highlights cost and access barriers to uptake of preferred CDI therapy.
At MAD-ID 2025, Rachel M. Kenney, PharmD, discusses treatment shifts, microbiome innovations, and pharmacists' roles in optimizing outcomes.
Timmy Do, PharmD, BCIDP, BCPS, presents case series at MAD-ID 2025 on investigational therapies following tecovirimat failure.
At MAD-ID 2025, Cadhan McFadden presents data from a multidisciplinary ambulatory care project using PEN-FAST scoring and oral challenges to improve antibiotic access and accuracy.
A new study being presented at MAD-ID looked at this class of therapies vs oral penicillins and found the former to be non-inferior to the latter.
